Injectable lipid emulsions, for decades, have been clinically used as an energy source for hospitalized patients by providing essential fatty acids and vitamins. Recent interest in utilizing lipid emulsions for delivering lipid soluble therapeutic agents, intravenously, has been continuously growing due to the biocompatible nature of the lipid-based delivery systems. Advancements in the area of novel lipids (olive oil and fish oil) have opened a new area for future clinical application of lipid-based injectable delivery systems that may provide a better safety profile over traditionally used long- and medium-chain triglycerides to critically ill patients. Formulation components and process parameters play critical role in the success of lipid injectable emulsions as drug delivery vehicles and hence need to be well integrated in the formulation development strategies. Physico-chemical properties of active therapeutic agents significantly impact pharmacokinetics and tissue disposition following intravenous administration of drug-containing lipid emulsion and hence need special attention while selecting such delivery vehicles. In summary, this review provides a broad overview of recent advancements in the field of novel lipids, opportunities for intravenous drug delivery, and challenges associated with injectable lipid emulsions.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Vinnars E, Hammarqvist F. 25th Arvid Wretlind’s Lecture—Silver anniversary, 25 years with ESPEN, the history of nutrition. Clin Nutr. 2004;23:955–62.
Wretlind A. Development of fat emulsions. JPEN J Parenter Enteral Nutr. 1981;5:230–5.
Vinnars E, Wilmore D. Jonathan roads symposium papers. History of parenteral nutrition. JPEN J Parenter Enteral Nutr. 2003;27:225–31.
de Meijer VE, Gura KM, Le HD, Meisel JA, Puder M. Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr. 2009;33:541–7.
Raghunathji NB, Albert EC, Madurai G, Charles ES, inventors; Emulsion compositions for the parenteral and/or oral administration of sparingly water soluble ionizable hydrophobic drugs patent EP0215313. 1992.
Calder PC, Jensen GL, Koletzko BV, Singer P, Wanten GJ. Lipid emulsions in parenteral nutrition of intensive care patients: current thinking and future directions. Intensive Care Med. 2010;36:735–49.
Waitzberg DL, Torrinhas RS, Jacintho TM. New parenteral lipid emulsions for clinical use. JPEN J Parenter Enteral Nutr. 2006;30:351–67.
Carpentier YA, Dupont IE. Advances in intravenous lipid emulsions. World J Surg. 2000;24:1493–7.
Furst P, Kuhn KS. Fish oil emulsions: what benefits can they bring? Clin Nutr. 2000;19:7–14.
Calder PC. Hot topics in parenteral nutrition. Rationale for using new lipid emulsions in parenteral nutrition and a review of the trials performed in adults. Proc Nutr Soc. 2009;68:252–60.
Battistella FD, Widergren JT, Anderson JT, Siepler JK, Weber JC, MacColl K. A prospective, randomized trial of intravenous fat emulsion administration in trauma victims requiring total parenteral nutrition. J Trauma. 1997;43:52–8. discussion 8–60.
Lenssen P, Bruemmer BA, Bowden RA, Gooley T, Aker SN, Mattson D. Intravenous lipid dose and incidence of bacteremia and fungemia in patients undergoing bone marrow transplantation. Am J Clin Nutr. 1998;67:927–33.
Clayton PT, Bowron A, Mills KA, Massoud A, Casteels M, Milla PJ. Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease. Gastroenterology. 1993;105:1806–13.
Ulrich H, Pastores SM, Katz DP, Kvetan V. Parenteral use of medium-chain triglycerides: a reappraisal. Nutrition. 1996;12:231–8.
Manuel-y-Keenoy B, Nonneman L, De Bosscher H, Vertommen J, Schrans S, Klutsch K, et al. Effects of intravenous supplementation with alpha-tocopherol in patients receiving total parenteral nutrition containing medium- and long-chain triglycerides. Eur J Clin Nutr. 2002;56:121–8.
Radermacher P, Santak B, Strobach H, Schror K, Tarnow J. Fat emulsions containing medium chain triglycerides in patients with sepsis syndrome: effects on pulmonary hemodynamics and gas exchange. Intensive Care Med. 1992;18:231–4.
Gogos CA, Kalfarentzos FE, Zoumbos NC. Effect of different types of total parenteral nutrition on T-lymphocyte subpopulations and NK cells. Am J Clin Nutr. 1990;51:119–22.
Gogos CA, Zoumbos N, Makri M, Kalfarentzos F. Medium- and long-chain triglycerides have different effects on the synthesis of tumor necrosis factor by human mononuclear cells in patients under total parenteral nutrition. J Am Coll Nutr. 1994;13:40–4.
Bach AC, Babayan VK. Medium-chain triglycerides: an update. Am J Clin Nutr. 1982;36:950–62.
Bach AC, Storck D, Meraihi Z. Medium-chain triglyceride-based fat emulsions: an alternative energy supply in stress and sepsis. JPEN J Parenter Enteral Nutr. 1988;12:82S–8.
Chambrier C, Lauverjat M, Bouletreau P. Structured triglyceride emulsions in parenteral nutrition. Nutr Clin Pract. 2006;21:342–50.
Lindgren BF, Ruokonen E, Magnusson-Borg K, Takala J. Nitrogen sparing effect of structured triglycerides containing both medium-and long-chain fatty acids in critically ill patients; a double blind randomized controlled trial. Clin Nutr. 2001;20:43–8.
Lin M-T, Yeh S-L, Tsou S-S, Wang M-Y, Chen W-J. Effects of parenteral structured lipid emulsion on modulating the inflammatory response in rats undergoing a total gastrectomy. Nutrition. 2009;25:115–21.
Wanten GJ, Calder PC. Immune modulation by parenteral lipid emulsions. Am J Clin Nutr. 2007;85:1171–84.
Sala-Vila A, Barbosa VM, Calder PC. Olive oil in parenteral nutrition. Curr Opin Clin Nutr Metab Care. 2007;10:165–74.
Garcia-de-Lorenzo A. Monounsaturated fatty acid-based lipid emulsions in critically ill patients are associated with fewer complications. Br J Nutr. 2006;95:1029.
Waitzberg DL, Torrinhas RS. Fish oil lipid emulsions and immune response: what clinicians need to know. Nutr Clin Pract. 2009;24:487–99.
Diprivan Injectable Emulsion. AstraZeneca. Available at: http://www1.astrazeneca-us.com/pi/diprivan.pdf. Accessed 23 March 2010.
Rossi J, Leroux J-C. Principles in the Development of Intravenous Lipid Emulsions. In: Wasan KM, editor. Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery. New York: Wiley; 2006. p. 88–123.
Floyd AG, Jain S. Injectable emulsions and suspensions. In: Lieberman HA, Rieger MM, Banker GS, editors. Pharmaceutical dosage forms: dispersed systems. New York: Marcel Dekker; 1996. p. 261–310.
Levy MY, Langerman L, Gottschalk-Sabag S, Benita S. Side-effect evaluation of a new diazepam formulation: venous sequela reduction following intravenous (i.v.) injection of a diazepam emulsion in rabbits. Pharm Res. 1989;6:510–6.
von Dardel O, Mebius C, Mossberg T, Svensson B. Fat emulsion as a vehicle for diazepam. A study of 9492 patients. Br J Anaesth. 1983;55:41–7.
Lovell MW, Johnson HW, Hui HW, Cannon JB, Gupta PK, Hsu CC. Less-painful emulsion formulations for intravenous administration of clarithromycin. Int J Pharm. 1994;109:45–57.
Suttmann H, Doenicke A, Kugler J, Laub M. A new formulation of etomidate in lipid emulsion—bioavailability and venous provocation. Anaesthesist. 1989;38:421–3.
Selander D, Curelaru I, Stefansson T. Local discomfort and thrombophlebitis following intravenous injection of diazepam. A comparison between a glycoferol-water solution and a lipid emulsion. Acta Anaesthesiol Scand. 1981;25:516–8.
Venkataram S, Awni WM, Jordan K, Rahman YE. Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. J Pharm Sci. 1990;79:216–9.
Constantinides PP, Lambert KJ, Tustian AK, Schneider B, Lalji S, Ma W, et al. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm Res. 2000;17:175–82.
Tibell A, Larsson M, Alvestrand A. Dissolving intravenous cyclosporin A in a fat emulsion carrier prevents acute renal side effects in the rat. Transpl Int. 1993;6:69–72.
Lamb KA, Washington C, Davis SS, Denyer SP. Toxicity of amphotericin B emulsion to cultured canine kidney cell monolayers. J Pharm Pharmacol. 1991;43:522–4.
Forster D, Washington C, Davis SS. Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. J Pharm Pharmacol. 1988;40:325–8.
Eccleston GM. Emulsions and Microemulsions. In: Swarbrick J, editor. Encylopedia of Pharmaceutical Technology. New York: Informa Healthcare USA. Inc; 2007. p. 1548–65.
Cannon BJ, Shi Y, Gupta P. Emulsions, microemulsions, and lipid-based drug delivery systems for drug solubilization and delivery—Part I: parenteral applications. In: Rong L, editor. Water-Insoluble Drug Formulation. New York: Taylor & Francis; 2008. p. 195–226.
Rensen PC, van Dijk MC, Havenaar EC, Bijsterbosch MK, Kruijt JK, van Berkel TJ. Selective liver targeting of antivirals by recombinant chylomicrons—a new therapeutic approach to hepatitis B. Nat Med. 1995;1:221–5.
Ishida E, Managit C, Kawakami S, Nishikawa M, Yamashita F, Hashida M. Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice. Pharm Res. 2004;21:932–9.
Yeeprae W, Kawakami S, Higuchi Y, Yamashita F, Hashida M. Biodistribution characteristics of mannosylated and fucosylated O/W emulsions in mice. J Drug Target. 2005;13:479–87.
Floyd AG. Top ten considerations in the development of parenteral emulsions. Pharm Sci Technol Today. 1999;2:134–43.
Kan P, Chen Z-B, Lee C-J, Chu IM. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J Control Release. 1999;58:271–8.
Constantinides PP, Tustian A, Kessler DR. Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev. 2004;56:1243–55.
Strickley RG, Anderson BD. Solubilization and stabilization of an anti-HIV thiocarbamate, NSC 629243, for parenteral delivery, using extemporaneous emulsions. Pharm Res. 1993;10:1076–82.
Herman CJ, Groves MJ. Hydrolysis kinetics of phospholipids in thermally stressed intravenous lipid emulsion formulations. J Pharm Pharmacol. 1992;44:539–42.
Wheeler JJ, Wong KF, Ansell SM, Masin D, Bally MB. Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci. 1994;83:1558–64.
Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA. 1991;88:11460–4.
Liu F, Liu D. Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm Res. 1995;12:1060–4.
Benita S, Friedman D, Weinstock M. Physostigmine emulsion: a new injectable controlled release delivery system. Int J Pharm. 1986;30:47–55.
Levy MY, Benita S. Design and characterization of a submicronized o/w emulsion of diazepam for parenteral use. Int J Pharm. 1989;54:103–12.
Jumaa M, Müller BW. Physicochemical properties of chitosan-lipid emulsions and their stability during the autoclaving process. Int J Pharm. 1999;183:175–84.
Buszello K, Muller BW. Emulsions as drug delivery systems. In: Nielloud F, Marti-Mestres G, editors. Pharmaceutical Emulsions and Suspensions. New York: Marcel Dekker; 2000. p. 191–229.
Hansrani PK, Davis SS, Groves MJ. The preparation and properties of sterile intravenous emulsions. J Parenter Sci Technol. 1983;37:145–50.
Washington C. Stability of lipid emulsions for drug delivery. Adv Drug Deliv Rev. 1996;20:131–45.
Benita S, Levy MY. Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterization. J Pharm Sci. 1993;82:1069–79.
Han J, Washington C. Partition of antimicrobial additives in an intravenous emulsion and their effect on emulsion physical stability. Int J Pharm. 2005;288:263–71.
Propofol Injectable Emulsion 1%. Hospira Inc. Available at: http://www.hospira.com/Products/productcatalog.aspx. Accessed 11 July 2010.
Driscoll DF, Dunbar JG, Marmarou A. Fat-globule size in a propofol emulsion containing sodium metabisulfite. Am J Health Syst Pharm. 2004;61:1276–80.
Collins-Gold LC, Lyons RT, Bartholow LC. Parenteral emulsions for drug delivery. Adv Drug Deliv Rev. 1990;5:189–208.
Washington C, Davis SS. The production of parenteral feeding emulsions by Microfluidizer. Int J Pharm. 1988;44:169–76.
Innocente N, Biasutti M, Venir E, Spaziani M, Marchesini G. Effect of high-pressure homogenization on droplet size distribution and rheological properties of ice cream mixes. J Dairy Sci. 2009;92:1864–75.
USP. <729>Globule size distribution in Lipid Injectable Emulsions. The United states Pharmacopeia 33/National Formulary 28; 2009. pp. 314–6.
USP. Lipid injectable emulsions. The United States Pharmacopeia 33/National Formulary 28; 2009. pp. 3641–3.
Akkar A, Müller RH. Intravenous itraconazole emulsions produced by SolEmuls technology. Eur J Pharm Biopharm. 2003;56:29–36.
Singh M, Ravin LJ. Parenteral emulsions as drug carrier systems. J Parenter Sci Technol. 1986;40:34–41.
Akkar A, Müller RH. Formulation of intravenous Carbamazepine emulsions by SolEmuls® technology. Eur J Pharm Biopharm. 2003;55:305–12.
Müller RH, Schmidt S, Buttle I, Akkar A, Schmitt J, Brömer S. SolEmuls®–novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int J Pharm. 2004;269:293–302.
Junghanns JU, Buttle I, Muller RH, Araujo IB, Silva AK, Egito ES, et al. SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs. Pharm Dev Technol. 2007;12:437–45.
Sila-on W, Vardhanabhuti N, Ongpipattanakul B, Kulvanich P. Influence of incorporation methods on partitioning behavior of lipophilic drugs into various phases of a parenteral lipid emulsion. AAPS PharmSciTech. 2008;9:684–92.
Ferezou J, Bach AC. Structure and metabolic fate of triacylglycerol- and phospholipid-rich particles of commercial parenteral fat emulsions. Nutrition. 1999;15:44–50.
Federal Register 56 (198); 51354, October 11, 1991.
Haskell RJ, Shifflett JR, Elzinga PA. Particle-sizing technologies for submicron emulsions. In: Benita S, editor. Submicron emulsions in drug targeting and delivery. Amsterdam: Harwood Academic Publisher; 1998. p. 21–98.
Jiao J, Burgess BJ. Characterization and Analysis of Dispersed Systems. In: Burgess BJ, editor. Injectable Dispersed Systems: Formulation, Processing, and Performance. New York: Taylor & Francis; 2005. p. 77–116.
Roland I, Piel G, Delattre L, Evrard B. Systematic characterization of oil-in-water emulsions for formulation design. Int J Pharm. 2003;263:85–94.
Sherman P. Rheological properties of emulsions. In: Becher P, editor. Encylopedia of Emulsion Technology. New York: Marcel Dekker; 1983. p. 405.
Herman CJ, Groves MJ. The influence of free fatty acid formation on the pH of phospholipid-stabilized triglyceride emulsions. Pharm Res. 1993;10:774–6.
Driscoll DF. Lipid injectable emulsions: pharmacopeial and safety issues. Pharm Res. 2006;23:1959–69.
Washington C. Drug release from microdisperse systems: a critical review. Int J Pharm. 1990;58:1–12.
Washington C. Evaluation of non-sink dialysis methods for the measurement of drug release from colloids: effects of drug partition. Int J Pharm. 1989;56:71–4.
Chidambaram N, Burgess DJ. A novel in vitro release method for submicron sized dispersed systems. AAPS PharmSci. 1999;1:E11.
Chidambaram N, Burgess BJ. Emulsions: design and manufacturing. In: Burgess BJ, editor. Injectable dispersed systems: formulation, processing, and performance. New York: Taylor & Francis; 2005. p. 213–41.
Tadros T, Izquierdo P, Esquena J, Solans C. Formation and stability of nano-emulsions. Adv Colloid Interface Sci. 2004;108–109:303–18.
Ishii F, Sasaki I, Ogata H. Effect of phospholipid emulsifiers on physicochemical properties of intravenous fat emulsions and/or drug carrier emulsions. J Pharm Pharmacol. 1990;42:513–5.
Benita S, Levy MY. Design and characterization of a submicronized o/w emulsion of Diazepam for parenteral use. Int J Pharm. 1989;54:103–12.
Jumaa M, Müller BW. The effect of oil components and homogenization conditions on the physicochemical properties and stability of parenteral fat emulsions. Int J Pharm. 1998;163:81–9.
Jumaa M, Muller BW. Lipid emulsions as a novel system to reduce the hemolytic activity of lytic agents: mechanism of the protective effect. Eur J Pharm Sci. 2000;9:285–90.
Trotta M, Pattarino F, Ignoni T. Stability of drug-carrier emulsions containing phosphatidylcholine mixtures. Eur J Pharm Biopharm. 2002;53:203–8.
Jafari SM, He Y, Bhandari B. Production of sub-micron emulsions by ultrasound and microfluidization techniques. J Food Eng. 2007;82:478–88.
Zeringue HJ, Brown ML, Singleton WS. Chromatographically homogeneous egg lecithin as stabilizer of emulsions for intravenous nutrition. J Am Oil Chem Soc. 1964;41:688–91.
Ishii F, Nii T. Properties of various phospholipid mixtures as emulsifiers or dispersing agents in nanoparticle drug carrier preparations. Colloids Surf B Biointerfaces. 2005;41:257–62.
Rydhag L. The importance of the phase behaviour of phospholipids for emulsion stability. Fette Seifen Anstrichm. 1979;81:168–73.
Rubino JT. The influence of charged lipids on the flocculation and coalescence of oil-in-water emulsions. II: electrophoretic properties and monolayer film studies. J Parenter Sci Technol. 1990;44:247–52.
Nii T, Ishii F. Properties of various phosphatidylcholines as emulsifiers or dispersing agents in microparticle preparations for drug carriers. Colloids Surf B. 2004;39:57–63.
Kawaguchi E, Shimokawa K-i, Ishii F. Physicochemical properties of structured phosphatidylcholine in drug carrier lipid emulsions for drug delivery systems. Colloids Surf B Biointerfaces. 2008;62:130–5.
Sznitowska M, Janicki S, Dabrowska E, Zurowska-Pryczkowska K. Submicron emulsions as drug carriers. Studies on destabilization potential of various drugs. Eur J Pharm Sci. 2001;12:175–9.
Groves MJ, Herman CJ. The redistribution of bulk aqueous phase phospholipids during thermal stressing of phospholipid-stabilized emulsions. J Pharm Pharmacol. 1993;45:592–6.
Jumaa M, Müller BW. The stabilization of parenteral fat emulsion using non-ionic ABA copolymer surfactant. Int J Pharm. 1998;174:29–37.
Jumaa M, Muller BW. Parenteral emulsions stabilized with a mixture of phospholipids and PEG-660-12-hydroxy-stearate: evaluation of accelerated and long-term stability. Eur J Pharm Biopharm. 2002;54:207–12.
Chaturvedi PR, Patel NM, Lodhi SA. Effect of terminal heat sterilization on the stability of phospholipid-stabilized submicron emulsions. Acta Pharm Nord. 1992;4:51–5.
Carpentier YA. Intravascular metabolism of fat emulsions: the Arvid Wretlind Lecture, ESPEN 1988. Clin Nutr. 1989;8:115–25.
Dupont IE, Carpentier YA. Clinical use of lipid emulsions. Curr Opin Clin Nutr Metab Care. 1999;2:139–45.
Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Hisaoka M. Pharmacokinetics of highly lipophilic antitumor agent palmitoyl rhizoxin incorporated in lipid emulsions in rats. Biol Pharm Bull. 1996;19:252–8.
Tibell A, Lindholm A, Sawe J, Chen G, Norrlind B. Cyclosporin A in fat emulsion carriers: experimental studies on pharmacokinetics and tissue distribution. Pharmacol Toxicol. 1995;76:115–21.
Hosokawa T, Yamauchi M, Yamamoto Y, Iwata K, Mochizuki H, Kato Y. Role of the lipid emulsion on an injectable formulation of lipophilic KW-3902, a newly synthesized adenosine A1-receptor antagonist. Biol Pharm Bull. 2002;25:492–8.
Ames MM, Kovach JS. Parenteral formulation of hexamethylmelamine potentially suitable for use in man. Cancer Treat Rep. 1982;66:1579–81.
Dundee JW, Clarke RS. Propofol. Eur J Anaesthesiol. 1989;6:5–22.
Lu Y, Zhang Y, Yang Z, Tang X. Formulation of an intravenous emulsion loaded with a clarithromycin-phospholipid complex and its pharmacokinetics in rats. Int J Pharm. 2009;366:160–9.
Takino T, Konishi K, Takakura Y, Hashida M. Long circulating emulsion carrier systems for highly lipophilic drugs. Biol Pharm Bull. 1994;17:121–5.
Sakaeda T, Hirano K. O/W lipid emulsions for parenteral drug delivery. II. Effect of composition on pharmacokinetics of incorporated drug. J Drug Target. 1995;3:221–30.
Sakaeda T, Hirano K. O/W lipid emulsions for parenteral drug delivery. III. Lipophilicity necessary for incorporation in oil particles even after intravenous injection. J Drug Target. 1998;6:119–27.
Ganta S, Paxton JW, Baguley BC, Garg S. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. Int J Pharm. 2008;360:115–21.
Shi S, Chen H, Lin X, Tang X. Pharmacokinetics, tissue distribution and safety of cinnarizine delivered in lipid emulsion. Int J Pharm. 2010;383:264–70.
Gao K, Sun J, Liu K, Liu X, He Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm. 2008;34:1227–37.
Azevedo CH, Carvalho JP, Valduga CJ, Maranhao RC. Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma. Gynecol Oncol. 2005;97:178–82.
Matsuo H. Preliminary evaluation of AS-013 (prodrug of prostaglandin E1) administration for chronic peripheral arterial occlusive disease. Int J Angiology. 1998;7:22–4.
Rodrigues DG, Maria DA, Fernandes DC, Valduga CJ, Couto RD, Ibanez OC, et al. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother Pharmacol. 2005;55:565–76.
Jang JH, Kim CK, Choi HG, Sung JH. Preparation and evaluation of 2-(allylthio)pyrazine-loaded lipid emulsion with enhanced stability and liver targeting. Drug Dev Ind Pharm. 2009;35:363–8.
Nishikawa M, Takakura Y, Hashida M. Biofate of fat emulsions. In: Benita S, editor. Submicron emulsions in drug targeting and delivery. Amsterdam: Harwood Academic Publisher; 1998. p. 99–118.
Deckelbaum RJ, Calder PC, Carpentier YA. Using different intravenous lipids: underutilized therapeutic approaches? Curr Opin Clin Nutr Metab Care. 2004;7:113–5.
Kruimel JW, Naber TH, van der Vliet JA, Carneheim C, Katan MB, Jansen JB. Parenteral structured triglyceride emulsion improves nitrogen balance and is cleared faster from the blood in moderately catabolic patients. JPEN J Parenter Enteral Nutr. 2001;25:237–44.
Oliveira FL, Rumsey SC, Schlotzer E, Hansen I, Carpentier YA, Deckelbaum RJ. Triglyceride hydrolysis of soy oil vs fish oil emulsions. JPEN J Parenter Enteral Nutr. 1997;21:224–9.
Qi K, Seo T, Jiang Z, Carpentier YA, Deckelbaum RJ. Triglycerides in fish oil affect the blood clearance of lipid emulsions containing long- and medium-chain triglycerides in mice. J Nutr. 2006;136:2766–72.
Qi K, Seo T, Al-Haideri M, Worgall TS, Vogel T, Carpentier YA, et al. Omega-3 triglycerides modify blood clearance and tissue targeting pathways of lipid emulsions. Biochemistry. 2002;41:3119–27.
Maranhao RC, Tercyak AM, Redgrave TG. Effects of cholesterol content on the metabolism of protein-free emulsion models of lipoproteins. Biochim Biophys Acta. 1986;875:247–55.
Handa T, Eguchi Y, Miyajima K. Effects of cholesterol and cholesteryl oleate on lipolysis and liver uptake of triglyceride/phosphatidylcholine emulsions in rats. Pharm Res. 1994;11:1283–7.
Clark SB, Derksen A, Small DM. Plasma clearance of emulsified triolein in conscious rats: effects of phosphatidylcholine species, cholesterol content and emulsion surface physical state. Exp Physiol. 1991;76:39–52.
Lenzo NP, Martins I, Mortimer BC, Redgrave TG. Effects of phospholipid composition on the metabolism of triacylglycerol, cholesteryl ester and phosphatidylcholine from lipid emulsions injected intravenously in rats. Biochim Biophys Acta. 1988;960:111–8.
Clark SB, Derksen A. Phosphatidylcholine composition of emulsions influences triacylglycerol lipolysis and clearance from plasma. Biochim Biophys Acta. 1987;920:37–46.
Illum L, Washington C, Davis SS. The effect of stabilising agents on the organ distribution of lipid emulsions. Int J Pharm. 1989;54:41–9.
Lee M-J, Lee M-H, Shim C-K. Inverse targeting of drugs to reticuloendothelial system-rich organs by lipid microemulsion emulsified with poloxamer 338. Int J Pharm. 1995;113:175–87.
Ueda K, Yamazaki Y, Noto H, Teshima Y, Yamashita C, Sakaeda T, et al. Effect of oxyethylene moieties in hydrogenated castor oil on the pharmacokinetics of menatetrenone incorporated in O/W lipid emulsions prepared with hydrogenated castor oil and soybean oil in rats. J Drug Target. 2003;11:37–43.
Arimoto I, Matsumoto C, Tanaka M, Okuhira K, Saito H, Handa T. Surface composition regulates clearance from plasma and triolein lipolysis of lipid emulsions. Lipids. 1998;33:773–9.
Morita SY, Okuhira K, Tsuchimoto N, Vertut-Doi A, Saito H, Nakano M, et al. Effects of sphingomyelin on apolipoprotein E- and lipoprotein lipase-mediated cell uptake of lipid particles. Biochim Biophys Acta. 2003;1631:169–76.
Redgrave TG, Rakic V, Mortimer BC, Mamo JC. Effects of sphingomyelin and phosphatidylcholine acyl chains on the clearance of triacylglycerol-rich lipoproteins from plasma. Studies with lipid emulsions in rats. Biochim Biophys Acta. 1992;1126:65–72.
Reddy PR, Venkateswarlu V. Pharmacokinetics and tissue distribution of etoposide delivered in long circulating parenteral emulsion. J Drug Target. 2005;13:543–53.
Chung H, Kim TW, Kwon M, Kwon IC, Jeong SY. Oil components modulate physical characteristics and function of the natural oil emulsions as drug or gene delivery system. J Control Release. 2001;71:339–50.
Nii T, Ishii F. Dialkylphosphatidylcholine and egg yolk lecithin for emulsification of various triglycerides. Colloids Surf B Biointerfaces. 2005;41:305–11.
Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Sasagawa K, et al. Lipid emulsions of palmitoylrhizoxin: effects of composition on lipolysis and biodistribution. Biopharm Drug Dispos. 1996;17:331–42.
Lutz O, Meraihi Z, Mura JL, Frey A, Riess GH, Bach AC. Fat emulsion particle size: influence on the clearance rate and the tissue lipolytic activity. Am J Clin Nutr. 1989;50:1370–81.
Takino T, Nagahama E, Sakaeda T, Yamashita F, Takakura Y, Hashida M. Pharmacokinetic disposition analysis of lipophilic drugs injected with various lipid carriers in the single-pass rat liver perfusion system. Int J Pharm. 1995;114:43–54.
Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Sasagawa K, et al. Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice. Pharm Res. 1996;13:305–10.
Cleviprex Injectable Emulsion. Orange book. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm. Accessed 11 July 2010.
Erickson AL, DeGrado JR, Fanikos JR. Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy. 2010;30:515–28.
Klang S, Benita S. Design and evaluation of submicron emulsions as colloidal drug carriers for intravenous adminsitration. In: Benita S, editor. Submicron emulsions in drug targeting and delivery. Amsterdam: Harwood Academic Publishers; 1998. p. 119–52.
Klang S, Parnas M, Benita S. Emulsions as drug carriers—possibilities, limitations and future prespectives. In: Muller RH, Benita S, Bohm B, editors. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Stuttgart: Medpharm Scientific Publishers; 1998. p. 31–60.
Wabel C (1998). Influence of lecithin on structure and stability of parenteral fat emulsions. Ph.D. thesis, University Erlangen-Nuremberg.
Wang J, Maitani Y, Takayama K. Antitumor effects and pharmacokinetics of aclacinomycin A carried by injectable emulsions composed of vitamin E, cholesterol, and PEG-lipid. J Pharm Sci. 2002;91:1128–34.
Chansri N, Kawakami S, Yamashita F, Hashida M. Inhibition of liver metastasis by all-trans retinoic acid incorporated into O/W emulsions in mice. Int J Pharm. 2006;321:42–9.
Suzuki S, Kawakami S, Chansri N, Yamashita F, Hashida M. Inhibition of pulmonary metastasis in mice by all-trans retinoic acid incorporated in cationic liposomes. J Control Release. 2006;116:58–63.
Kleberg K, Jacobsen F, Fatouros DG, Müllertz A. Biorelevant media simulating fed state intestinal fluids: colloid phase characterization and impact on solubilization capacity. J Pharm Sci. 2010;99:3522–32.
Fernandes PB, Hardy DJ, McDaniel D, Hanson CW, Swanson RN. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother. 1989;33:1531–4.
Bravo Gonzalez RC, Huwyler J, Walter I, Mountfield R, Bittner B. Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. Int J Pharm. 2002;245:143–51.
Qiu Y, Gao Y, Hu K, Li F. Enhancement of skin permeation of docetaxel: a novel approach combining microneedle and elastic liposomes. J Control Release. 2008;129:144–50.
Sakaeda T, Kakushi H, Shike T, Takano K, Harauchi T, Hirata M, et al. O/W lipid emulsions for parenteral drug delivery. IV. Changes in the pharmacokinetics and pharmacodynamics of a highly lipophilic drug, menatetrenone. J Drug Target. 1998;6:183–9.
Guest Editors: Lavinia Lewis, Jim Agalloco, Bill Lambert, Russell Madsen, and Mark Staples
Rights and permissions
About this article
Cite this article
Hippalgaonkar, K., Majumdar, S. & Kansara, V. Injectable Lipid Emulsions—Advancements, Opportunities and Challenges. AAPS PharmSciTech 11, 1526–1540 (2010). https://doi.org/10.1208/s12249-010-9526-5
- lipid emulsions
- parenteral formulations